Robberecht P, Tatemoto K, Chatelain P, Waelbroeck M, Delhaye M, Taton G, De Neef P, Camus J C, Heuse D, Christophe J
Regul Pept. 1982 Oct;4(5):241-50. doi: 10.1016/0167-0115(82)90117-3.
The presence of receptors, recognized by vasoactive intestinal peptide (VIP) as well as by PHI (a peptide with N-terminal histidine and C-terminal isoleucine amide), was documented in lung membranes from rat, mouse, guinea pig and man by the ability of these receptors, once occupied, to stimulate adenylate cyclase. In lung membranes from rat, mouse and guinea pig, the capacity of VIP, PHI and secretin to stimulate the enzyme and the potency of the same peptides to compete with 125I-VIP for binding to VIP receptors were similar, the affinity decreasing in the order: VIP greater than PHI greater than secretin. In addition, dose-effect curves were compatible with the coexistence of high-affinity and low-affinity VIP receptors, in the four animal species considered. If PHI was able to recognize all VIP receptors it could not, however, discriminate the subclasses of VIP receptors.
通过血管活性肠肽(VIP)以及PHI(一种N端为组氨酸、C端为异亮氨酸酰胺的肽)识别的受体,已在大鼠、小鼠、豚鼠和人类的肺膜中得到证实,这些受体一旦被占据,就能刺激腺苷酸环化酶。在大鼠、小鼠和豚鼠的肺膜中,VIP、PHI和促胰液素刺激该酶的能力以及这些肽与125I-VIP竞争结合VIP受体的效力相似,亲和力按以下顺序降低:VIP>PHI>促胰液素。此外,在所研究的四种动物中,剂量效应曲线与高亲和力和低亲和力VIP受体共存的情况相符。然而,如果PHI能够识别所有VIP受体,它却无法区分VIP受体的亚类。